Category Archives: Cancer Treatment

Researchers discover tumor suppressor gene in very aggressive lung cancer

In addition to identifying the tumor suppressor role of MAX in lung cancer, the group led by Montse Sanchez-Cespedes has unveiled a functional relationship between MAX and another tumor suppressor, BRG1, in virtue of which BRG1 regulates the expression of MAX through direct recruitment to the MAX promoter. However, the functional connection is even more complex. On one hand, the presence of BRG1 is required to activate neuroendocrine transcriptional programs and to up-regulate MYC-targets, such as glycolytic-related genes. Moreover, the depletion of BRG1 strongly hinders cell growth, specifically in MAX-deficient cells, heralding a synthetic lethal interaction. …

Cancer genomics hub adds childhood cancer data

A UCSC team led by bioinformatics expert David Haussler established CGHub in 2012 to manage primary sequence data from all of NCI’s cancer genomics research programs. These programs, which aim to improve cancer treatment by identifying the genetic drivers of cancer, require massive amounts of data to be shared among researchers throughout the country. …

Stopping tumors in their path

A GBM tumour contains a complex combination of different cell types, including ‘stem-like’ cells that are able to initiate brain tumour growth, even when present in very small numbers. These cells, known as brain-tumour initiating cells (BTICs), are believed to be among the cells that can re-initiate GBM if they are not completely eradicated through surgery, radiation and chemotherapy. Thus, BTICs represent an important therapeutic target for GBM treatment strategies. "We wanted to find out how GBM-derived BTICs are able to initiate a tumour with the ultimate goal of preventing the re-growth of this deadly form of brain cancer," says Dr…

New technique targets specific areas of cancer cells with different drugs

"In testing on laboratory mice, our technique resulted in significant improvement in breast cancer tumor reduction as compared to conventional treatment techniques," says Dr. Zhen Gu, senior author of a paper on the research and an assistant professor in the joint biomedical engineering program at NC State and UNC-Chapel Hill. …

Costs for complications from cancer surgical care extremely high

The authors’ findings come against the backdrop of rising cancer care costs in the United States, which were estimated at $124.6 billion in 2010 and could rise by 66 percent to $207 billion by 2020. "It is widely known that outcomes after cancer surgery vary widely, depending on interactions between patient, tumor, neoadjuvant therapy and provider factors," said Marah Short, a senior research analyst for the Baker Institute’s Health Policy Forum. "An area of cancer care that has received little attention is the influence of complications on medical outcomes and costs of care…

International team completes systematic, genomic study of cervical cancer

The study, which appears online in Nature, addresses a public health concern of global significance: cervical cancer is the second most common cancer in women and is responsible for approximately 10 percent of cancer deaths in women — particularly in developing countries where screening methods are not readily accessible. Almost all cases of the disease are caused by exposure to HPV and it is expected that vaccination efforts targeting HPV will decrease cervical cancer cases over time. In the meantime, however, the disease remains a significant threat to women’s health. …

Study identifies factors associated with pain one year after breast cancer surgery

"Persistent pain following breast cancer treatments remains a significant clinical problem despite improved treatment strategies. Data on factors associated with persistent pain are needed to develop prevention and treatment strategies and to improve the quality of life for breast cancer patients," according to background information in the article. Tuomo J. …

Novel non-invasive therapy prevents breast cancer formation in mice

The therapy emerged from a sophisticated effort to reverse-engineer gene networks to identify genes that drive cancer. The same strategy could lead to many new therapies that disable cancer-causing genes no current drugs can stop, and it also can be used to find therapies for other diseases…

Classic signaling pathway holds key to prostate cancer progression

Although it is well established that the androgen receptor is important for prostate cancer progression, it is unclear what drives this process. Frigo and his team demonstrated in this study that androgens take control of the AMPK signaling cascade, a master regulator of metabolism, to increase prostate cancer cell growth. "The androgen signaling cascade is important for understanding early and late-stage prostate cancer progression. …